Eton Pharmaceuticals, Inc. (NasdaqGM:ETON) made a stalking horse bid to acquire Certain assets including the Vistogard and Xuriden from Wellstat Therapeutics Corporation and Wellstat Biologics Corporation for $37 million on June 9, 2023. The transaction includes sell-side termination fee of $0.8 million. The deal will be financed through its cash on hand and certain commited financing. The transaction is subject to the approval of Bankruptcy Court.

Eton Pharmaceuticals, Inc. (NasdaqGM:ETON) cancelled the acquisition of Certain assets including the Vistogard and Xuriden from Wellstat Therapeutics Corporation and Wellstat Biologics Corporation on June 30, 2023.